Skip to main content
. 2018 Mar 1;11(3):1818–1824.

Table 4.

Associations between expression of the Hh signaling pathway components and the clinical/pathological characteristics of PTC patients

Total SHH (-/+) p-value PTCH (-/+) p-value SMO (-/+) p-value
Gender Female 130 47/83 0.726 44/86 0.583 56/74 0.227
Male 46 18/28 13/33 15/31
Age <45 115 40/75 0.418 36/79 0.736 49/66 0.424
≥45 61 25/36 21/40 22/39
Tumor size ≤2 cm 111 49/62 0.010 42/69 0.047 52/59 0.026
>2 cm 65 16/49 15/50 19/46
ETE Yes 25 4/21 0.024 3/22 0.020 5/20 0.028
No 151 61/90 54/97 66/85
LNM Yes 106 34/72 0.008 32/74 0.026 38/68 0.013
No 70 37/33 33/37 39/31
TNM stage I+II 138 49/89 0.455 47/91 0.436 54/84 0.578
III+IV 38 16/22 10/28 17/21

P-values based on the chi-square test; “-” (negative), “+” (positive). ETE, extrathyroidal extension; LNM, lymph node metastasis.